Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000176373 | SCV000228019 | pathogenic | not provided | 2014-10-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001380264 | SCV001578262 | pathogenic | Tuberous sclerosis 2 | 2020-12-22 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This sequence change affects an acceptor splice site in intron 22 of the TSC2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). Dirurption of this splice site has been observed in individual(s) with clinical features of tuberous sclerosis complex (PMID: 16981987, 29432982). ClinVar contains an entry for this variant (Variation ID: 49780). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TSC2 are known to be pathogenic (PMID: 10205261, 17304050). |
Genome- |
RCV001380264 | SCV002040956 | pathogenic | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Tuberous sclerosis database |
RCV000043045 | SCV000066844 | not provided | Tuberous sclerosis syndrome | no assertion provided | curation |